Literature DB >> 18470726

Molecular cancer vaccines: Tumor therapy using antigen-specific immunizations.

T Schweighoffer1.   

Abstract

Vaccination against tumors promises selective destruction of malignant cells by the host's immune system. Molecular cancer vaccines rely on recently identified tumor antigens as immunogens. Tumor antigens can be applied in many forms, as genes in recombinant vectors, as proteins or peptides representing T cell epitopes.Analysis of various aspects indicates some advantage for peptide-based vaccines over the other modalities. Further refinements and extensively monitored clinical trials are necessary to advance molecular cancer vaccines from concepts into powerful therapy.

Entities:  

Year:  1997        PMID： 18470726     DOI： 10.1007/BF02899917

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   2.874


  154 in total

1.  Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.

Authors:  T M Fu; J B Ulmer; M J Caulfield; R R Deck; A Friedman; S Wang; X Liu; J J Donnelly; M A Liu
Journal:  Mol Med       Date:  1997-06       Impact factor: 6.354

2.  Tumor cells expressing a recall antigen are powerful cancer vaccines.

Authors:  T Schweighoffer
Journal:  Eur J Immunol       Date:  1996-11       Impact factor: 5.532

3.  MHCPEP--a database of MHC-binding peptides: update 1995.

Authors:  V Brusic; G Rudy; A P Kyne; L C Harrison
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

4.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

Authors:  J C Skipper; R C Hendrickson; P H Gulden; V Brichard; A Van Pel; Y Chen; J Shabanowitz; T Wolfel; C L Slingluff; T Boon; D F Hunt; V H Engelhard
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

Review 5.  Experimental and clinical studies of cytokine gene-modified tumor cells.

Authors:  R I Tepper; J J Mulé
Journal:  Hum Gene Ther       Date:  1994-02       Impact factor: 5.695

6.  Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.

Authors:  X Kang; Y Kawakami; M el-Gamil; R Wang; K Sakaguchi; J R Yannelli; E Appella; S A Rosenberg; P F Robbins
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

7.  A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

Authors:  P van der Bruggen; J Bastin; T Gajewski; P G Coulie; P Boël; C De Smet; C Traversari; A Townsend; T Boon
Journal:  Eur J Immunol       Date:  1994-12       Impact factor: 5.532

8.  Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.

Authors:  A Vitiello; G Ishioka; H M Grey; R Rose; P Farness; R LaFond; L Yuan; F V Chisari; J Furze; R Bartholomeuz
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

9.  Epidermal cell presentation of tumor-associated antigens for induction of tolerance.

Authors:  K C Tan; J Hosoi; S Grabbe; A Asahina; R D Granstein
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

10.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Authors:  L Zitvogel; J I Mayordomo; T Tjandrawan; A B DeLeo; M R Clarke; M T Lotze; W J Storkus
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307
View more
  1 in total

Review 1.  Improvement of different vaccine delivery systems for cancer therapy.

Authors:  Azam Bolhassani; Shima Safaiyan; Sima Rafati
Journal:  Mol Cancer       Date:  2011-01-07       Impact factor: 27.401
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.